Insider Selling: Saints Capital Granite, L.P. Unloads 32,301 Shares of Enanta Pharmaceuticals Stock (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) major shareholder Saints Capital Granite, L.P. sold 32,301 shares of the stock on the open market in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $19.84, for a total value of $640,851.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 6.15% on Wednesday, hitting $20.81. The stock had a trading volume of 279,921 shares. Enanta Pharmaceuticals has a one year low of $14.31 and a one year high of $26.39. The stock’s 50-day moving average is $20.99 and its 200-day moving average is $19.47. The company’s market cap is $372.7 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.11. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.73 million. On average, analysts predict that Enanta Pharmaceuticals will post $-1.26 earnings per share for the current fiscal year.
Separately, analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 2nd. They now have a $25.40 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $27.20.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.